References
- 1.
World Health Organization. HIV [Internet]. Geneva (CH): [reviewed 2022 Nov 01; cited 2022 Nov 05]. Available from:
https://www.who.int/news-room/fact-sheets/detail/hiv-aids# .World Health Organization HIV [Internet] Geneva (CH) [reviewed 2022 Nov 01; cited 2022 Nov 05]. Available from:https://www.who.int/news-room/fact-sheets/detail/hiv-aids# - Couturier J, Suliburk JW, Brown JM, Luke DJ, Agarwal N, Yu X et al. Human adipose tissue as a reservoir for memory CD4+ T cells and HIV. AIDS. 2015 Mar 27;29(6):667–74. doi: 10.1097/QAD.0000000000000599.
- Anand AR, Rachel G, Parthasarathy D. HIV Proteins and Endothelial Dysfunction: Implications in Cardiovascular Disease. Front Cardiovasc Med. 2018 Dec 19;5:185. doi: 10.3389/fcvm.2018.00185.
- Grunfeld C. Dyslipidemia and its Treatment in HIV Infection. Top HIV Med. 2010 Aug–Sep;18(3):112–8.
- Carey D, Amin J, Boyd M, Petoumenos K, Emery S. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and metaanalysis of randomized controlled trials. J Antimicrob Chemother. 2010 Sep;65(9):1878–88. doi: 10.1093/jac/dkq231. Epub 2010 Jun 16.
- Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015 Mar;35(3):211–9. doi: 10.1007/s40261-014-0266-2.
- Lagathu C, Béréziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf. 2019 Sep;18(9):829–840. doi: 10.1080/14740338.2019.1644317. Epub 2019 Jul 19.
- Dubé MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):429–42. doi: 10.1016/j.beem.2011.04.004.
- Non LR, Escota GV, Powderly WG. HIV and its relationship to insulin resistance and lipid abnormalities. Transl Res. 2017 May;183:41–56. doi: 10.1016/j.trsl.2016.12.007. Epub 2016 Dec 23.
- Chachage M. The gut-microbiome contribution to HIVassociated cardiovascular disease and metabolic disorders. Current Opinion in Endocrine and Metabolic Research 2021; 21:100287.
- Chen YF, Dugas TR. Endothelial mitochondrial senescence accelerates cardiovascular disease in antiretroviral-receiving HIV patients. Toxicol Lett. 2019 Dec 15;317:13–23. doi: 10.1016/j.toxlet.2019.09.018.
- Waters DD, Hsue PY. Lipid Abnormalities in Persons Living With HIV Infection. Can J Cardiol. 2019 Mar;35(3):249–259. doi: 10.1016/j.cjca.2018.11.005.
- Rodés B, Cadiñanos J, Esteban-Cantos A, Rodríguez-Centeno J, Arribas JR. Ageing with HIV: Challenges and biomarkers. EBioMedicine. 2022 Mar;77:103896. doi: 10.1016/j.ebiom.2022.103896.
- The RESPOND Study Group. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS. 2021 May 1;35(6):869–882. doi: 10.1097/QAD.0000000000002811.
- Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020 Sep 12;71(6):1379–1389. doi: 10.1093/cid/ciz999.
- Bischoff J, Gu W, Schwarze-Zander C, Boesecke C, Wasmuth JC, van Bremen K et al. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). EClinicalMedicine. 2021 Sep 5;40:101116. doi: 10.1016/j.eclinm.2021.101116.
- Neesgaard B, Greenberg L, Miró JM, Grabmeier-Pfistershammer K, Wandeler G, Smith C et al. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Lancet HIV. 2022 Jul;9(7):e474–e485. doi: 10.1016/S2352-3018(22)00094-7.